is a dermorphin analog that shows high affinity and selectivity for the opioid receptor. The intrathecal potency of [Dmt 1
1
]DALDA far exceeded its affinity at receptors and suggests that other mechanisms must be involved in its action in the spinal cord. The affinity and selectivity of [Dmt 1 ]DALDA was determined using cell membranes expressing cloned human , ␦, and opioid receptors. ]DALDA, resulting in ED 50 of 6.2 (3.6 -12.6) pmol and 6.6 (3.5-19.6) pmol, respectively. Neither antisera had any effect on the response to i.t. morphine. Intracerebroventricular (i.c.v.) [Dmt 1 ]DALDA was not affected by previous i.c.v. administration of anti-Dyn or anti-ME. Pretreatment with norbinaltorphimine or naltriben also attenuated the antinociceptive response to i. Of the three subtypes of opioid receptors (, ␦, and ), appears to be most important in analgesia. [Dmt 1 ]DALDA (H-Dmt-D-Arg-Phe-Lys-NH 2 ; Dmt ϭ 2Ј,6Ј-dimethyltyrosine) is a dermorphin analog with extraordinary affinity (K d ϳ150 pM) and selectivity for receptors (Schiller et al., 2000) . [Dmt 1 ]DALDA was reported to be ϳ14,000 and ϳ150 times more selective for than ␦ and , respectively (Schiller et al., 2000) . Surprisingly, the in vivo analgesic potency of [Dmt 1 ]DALDA far exceeded its affinity and potency at receptors. Compared with morphine, [Dmt 1 ]DALDA was 30 to 200 times more potent after intracerebroventricular (i.c.v.) administration, and 1,000 to 5,000 times more potent after intrathecal (i.t.) administration (Neilan et al., 2001; Shimoyama et al., 2001; Riba et al., 2002; Zhao et al., 2002) . In contrast, the affinity of [Dmt 1 ]DALDA for the receptor was estimated to be only 7-fold greater compared with morphine (Schiller et al., 2000) . The extraordinary potency of intrathecal [Dmt 1 ]DALDA suggested that mechanisms other than activation of receptors must be involved in its analgesic action in the spinal cord. Previous studies using selective , ␦, and antagonists concluded that the antinociceptive action of [Dmt 1 ]DALDA was mediated via receptors, and that [Dmt 1 ]DALDA was interacting with the same population of spinal receptors as DAMGO (H-Tyr-D-Ala-Gly-NMePhe-Gly-ol) (Riba et al., 2002) . However, [Dmt 1 ]DALDA exhibited little to no cross-tolerance in morphine-tolerant animals, which led to the suggestion that [Dmt 1 ]DALDA and morphine may be acting at different subtypes of receptors (Neilan et al., 2001; Riba et al., 2002) . Differences in response to [Dmt 1 ]DALDA and morphine in different mice strains and with antisense oligodeoxynucleotides targeting against specific exons of the mouse opioid receptor gene support the suggestion that [Dmt 1 ]DALDA and morphine act at different subtypes of receptors (Neilan et al., 2001 ]DALDA and morphine in the spinal cord, but with little supraspinal tolerance (Zhao et al., 2002) . This recent finding raises the possibility that [Dmt 1 ]DALDA might act via different mechanisms in the spinal cord versus brain.
It was recently reported that endomorphin-1 and endomorphin-2, two opioid peptides isolated from mammalian brain, act via different mechanisms after i.t. administration. Both endomorphin peptides demonstrate high affinity and selectivity for receptors in radioligand binding assays (Zadina et al., 1997) . However, an additional component of the antinociceptive response to i.t. endomorphin-2 is due to the release of dynorphin A(1-17) and [Met 5 ]enkephalin which subsequently act on and ␦ receptors, respectively, in the spinal cord (Ohsawa et al., 2001; Sakurada et al., 2001) . Activation of ␦ and receptors can potentiate the action of opioid agonists in the spinal cord (Porreca et al., 1992; He and Lee, 1998 (Schiller et al., 1989 (Schiller et al., , 2000 Zhao et al., 2002) . Antisera. Rabbit antisera against dynorphin A(1-17) and [Met 5 ]enkephalin were obtained from Peninsula Laboratories/ Bachem (San Carlos, CA). According to the manufacturer, the antiserum against dynorphin A(1-17) showed 0.43% cross-reactivity with dynorphin A(1-13), but does not cross-react with dynorphin A (1-8 ]DALDA for 80 min at 25°C, and nonspecific binding was determined with 10 M naloxone. Free radioligand was separated from bound radioligand by rapid filtration through GF/B filters (Brandel, Gaithersburg, MD) with a cell harvester (Brandel). Filters were washed three times with 3 ml of Tris-HCl buffer. Radioactivity was determined by liquid scintillation counting. All binding experiments were carried out in triplicate, and the results represent mean Ϯ S.E. from four to six experiments. IC 50 was determined from the displacement curves using nonlinear regression (GraphPad, San Diego, CA). K i values were calculated from the IC 50 values by means of the Cheng and Prusoff equation,
, where L and K d are the concentration and affinity of the radiolabeled ligand in the assay (Cheng and Prusoff, 1973 ]DALDA for 60 min at 30°C. Nonspecific binding was determined using 10 M unlabeled GTP␥S. Free radioligand was separated from bound radioligand by rapid filtration. All experiments were carried out in triplicate, and the results represent data from four to six experiments. Potency (EC 50 ) and intrinsic activity (E max ) were determined using nonlinear regression (Graphpad). The EC 50 values are presented with 95% confidence intervals.
Drug Administration. Drugs were administered i.t., i.c.v., or subcutaneously (s.c.) to mice. Intrathecal injection was carried out according to the method described by Hylden and Wilcox (1980) . The needle (30-gauge) was inserted from the side of the L5 or L6 spinous process and the injection volume was 4 l/mouse. For i.c.v. injections, mice were lightly anesthetized with isoflurane and an incision made over the scalp to expose the bregma. The injection (4 l) was delivered 2 mm lateral and caudal to the bregma to a depth of 3 mm (Haley and McCormick, 1957) . Groups of 10 to 20 mice were used for each dose and each mouse was only used once. Potency was determined at 30 min after i. The radiant heat tail-flick assay was used for antinociceptive tests in mice. The light intensity was adjusted such that the baseline latencies ranged between 2.5 and 3.5 s. To avoid tissue damage, a cut-off of 10 s was used. Antinociceptive activity for each animal was expressed as percent of maximal possible effect (%MPE) which was calculated as (P2 Ϫ P1)/(10 Ϫ P1) ϫ 100, where P1 and P2 are predrug and postdrug response time, respectively. For dose-response analyses, the percentage of analgesic responders was calculated and the quantal dose-response curves analyzed using probit analysis (PharmTools Pro; McCary Group Inc., Elins Park, PA). Antinociception was defined as a latency response of greater than two times the baseline latency for an individual animal. Data are presented as ED 50 with 95% confidence intervals. Statistical comparisons of dose-response curves were performed by analysis of variance with F-Statistic (PharmTools Pro). (Schiller et al., 2000) . Because brain tissues express more than one subtype of opioid receptors and the specificity of these radioligands are not absolute, we have evaluated the selectivity of [Dmt 1 ]DALDA by determining its affinity in pure populations of , ␦, and receptors. Competitive displacement binding resulted in K i of 156 Ϯ 26 pM for hMOR membranes (n ϭ 6), 1.67 Ϯ 0.04 M for hDOR membranes (n ϭ 4), and 4.4 Ϯ 1.7 nM for hKOR membranes (n ϭ 4). This resulted in a /␦ selectivity of 10,700 and a / selectivity of 27. ]DALDA was previously determined using the guinea pig ileum and mouse vas deferens assays (Schiller et al., 2000) . Since both guinea pig ileum and mouse vas deferens contain more than one subtype of opioid receptors, we have compared the potency and intrinsic activity of ]DALDA was significantly reduced in mice pretreated with norBNI ( Fig. 2A ) and the ED 50 of i.t. [Dmt 1 ]DALDA was increased from 1.22 (0.59 -2.34) pmol to 11.6 (3.09 -44.8) pmol (P Ͻ 0.05) (Fig. 2B) . ]DALDA (4.1 pmol). This antiserum does not show cross-reactivity to dynorphin peptides. Figure 5A shows the reduction in antinociceptive response to i.t. ]DALDA from 1.22 pmol to 6.6 (3.5-19.6) pmol (P Ͻ 0.05) (Fig. 5B) . In contrast, i.c.v. pretreatment with the same dilution of [Met 5 ]enkephalin antiserum had no effect on the antinociceptive response to i.c.v. (Fig. 6A) (Fig. 6B) . This dose of naltriben also significantly reduced the antinociceptive response to i.t.
Effects of Pretreatment with
[Dmt 1 ]DALDA (Fig. 6B) . Dynorphin A(1-17) (Fig. 7) .
Effects of i.t. Pretreatment with Antisera against
Effects of Pretreatment with Naloxonazine on i. ]DALDA from 1.22 to 6.6 pmol (P Ͻ 0.05). Anti-ME, [Met 5 ]enkephalin antiserum; %MPE, percentage of maximal possible effect, as defined under Materials and Methods. (Schiller et al., 2000 ]DALDA and MOR membranes, was found to be 154 Ϯ 10 pM, and this is in excellent agreement with the K i reported previously (143 pM) (Schiller et al., 2000) . The /␦ selectivity of [Dmt 1 ]DALDA was found to be ϳ10,000, which is also similar to the earlier estimate (14,700) obtained from brain membranes (Schiller et al., 2000) and is similar to that reported for endomorphin-1 and endomorphin-2 (Zadina et al., 1997) . [Dmt 1 ]DALDA has modest affinity for KOR, and the MOR/KOR selectivity determined using pure receptor populations (27) is less than that previously determined in mouse brain membranes with selective radioligands (156) (Schiller et al., 2000) .
The present study provides the first report on the potency and intrinsic activity of [Dmt 1 ]DALDA at the three opioid receptors using GTP␥S binding as a measure of G protein ]enkephalin antiserum only has 2.8% cross-reactivity against [Leu 5 ]enkephalin and none against dynorphin A(1-17). These antisera had no effect on the antinociceptive response to intrathecal morphine, and i.c.v. administration of these antisera had no effect on supraspinal [Dmt 1 ]DALDA. This is consistent with the lack of effect of norBNI or naltriben on supraspinal [Dmt 1 ]DALDA. It was also noted in an earlier paper that norBNI and naltrindol (another ␦ antagonist) had no effect on supraspinal [Dmt 1 ]DALDA; however, their effect on spinal [Dmt 1 ]DALDA was not examined (Neilan et al., 2001 ). The enkephalin peptides mediate antinociception supraspinally and spinally by interacting with ␦ 1 and ␦ 2 receptors, respectively . In our study, the response to i.t. [Dmt 1 ]DALDA was attenuated by pretreatment with naltriben (␦ 2 antagonist), whereas naltriben had no effect on supraspinal [Dmt 1 ]DALDA. There is evidence that enkephalins and other ␦ agonists can potentiate the action of agonists in the spinal cord (Vaught and Takemori, 1979; Lee et al., 1980; He and Lee, 1998) , and the release of endogenous [Leu 5 ]enkephalin by swim-stress potentiated the antinociceptive potency of morphine (Vanderah et al., 1993 The role of dynorphin in pain modulation is highly controversial. Whereas low doses of dynorphin produce antinociception, higher doses produce a long-lasting allodynia ( Vanderah et al., 1996; Laughlin et al., 1997) . Many studies support an antinociceptive function of dynorphin in the spinal cord by negatively modulating transmission of nociceptive information. Dynorphin can inhibit substance P release (Zachariou and Goldstein, 1997) and inhibit synaptic transmission of nociceptive neurons in the spinal cord (Randic et al., 1995) via activation of receptors. On the other hand, dynorphin can exert pronociceptive effects via nonopioid mechanisms that involve N-methyl-D-aspartate receptors (Bakshi et al., 1992; Laughlin et al., 1997; Vanderah et al., 2000) . Recent data obtained with dream Ϫ/Ϫ mice clearly support an antinociceptive role for endogenous dynorphin. DREAM (downstream regulatory element antagonistic modulator) is a putative transcriptional repressor for the prodynorphin gene (Carrion et al., 1999) . Mice lacking DREAM had elevated levels of prodynorphin mRNA and dynorphin A peptides in the spinal cord and displayed reduced responses in models of acute thermal, mechanical, and visceral pain (Cheng et al., 2002) .
Activation of spinal release of dynorphin was reported to contribute to the intrathecal action of endomorphin-2, but not endomorphin-1 (Ohsawa et al., 2001; Sakurada et al., 2001) . The antinociceptive response to intrathecal endomorphin-2 was blocked by intrathecal pretreatment with antiserum against dynorphin A(1-17) or norBNI. However, spinal dynorphin does not appear to play a role in the spinal action of endomorphin-1 nor DAMGO (Sakurada et al., 2001 ). We also found no effect of dynorphin antiserum or norBNI on intrathecal morphine action. As the endomorphins and DAMGO are also highly selective agonists, these findings suggest that only certain agonists can elicit the release of dynorphin from the spinal cord. There is less evidence to support a role for endogenous enkephalins in the spinal action of other agonists. It was reported that [Met 5 ]enkephalin antiserum blocked the effect of intrathecal endomorphin-2 in one study (Sakurada et al., 2001) but not in another (Ohsawa et al., 2001) .
It has been proposed that these diverse agonists may activate different subtypes of receptors in the spinal cord (Sakurada et al., 1999 (Sakurada et al., , 2000 . Autoradiographic studies have demonstrated the presence of both 1 and 2 receptors in the brain and spinal cord (Moskowitz and Goodman, 1985) . Pretreatment with naloxonazine, the 1 antagonist, partially blocked the action of intrathecal endomorphin-2 but not endomorphin-1 or DAMGO, suggesting that activation of 1 receptors in the spinal cord leads to dynorphin release (Sakurada et al., 1999 (Sakurada et al., , 2001 . In another study, however, the authors reported that the same dose of naloxonazine blocked all three agonists, although endomorphin-2 was more sensitive compared with endomorphin-1 and DAMGO (Sakurada et al., 2000) . In general, available evidence suggests that 1 is involved in supraspinal but not spinal analgesia. In the present study, naloxonazine had no significant effect on either i.t. or i.c.v. [Dmt 1 ]DALDA, and this is consistent with findings reported earlier (Neilan et al., 2001) . In view of the confusion in the literature, and the lack of a molecular correlate for the pharmacologically defined 1 receptor, it is probably premature to speculate on receptor subtypes and mechanisms of spinal analgesia.
In summary, 
